06.01.2020, 20:42
Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics. The company’s cash cow is its valbenazine drug, which is marketed as Ingrezza. The drug is used to treat a condition called tardive dyskinesia, which causes tremors in patients with long-term use of antipsychotics. Ingrezza sales soared roughly 78% in the company’s third quarter to $198.1 million.
The company has been a solid medical growth stock and its most recent quarter can attest, as its total revenue soared over 46% in Q3 to $222 million. The medical giant has seen its shares climb over 3,800% in the 2010s and our estimates don’t see its growth stopping anytime soon.
....
.........
https://www.zacks.com/stock/news/684919/...txt-684919
![[Bild: NBIXc1dl1340.png]](https://finviz.com/publish/010620/NBIXc1dl1340.png)
The company has been a solid medical growth stock and its most recent quarter can attest, as its total revenue soared over 46% in Q3 to $222 million. The medical giant has seen its shares climb over 3,800% in the 2010s and our estimates don’t see its growth stopping anytime soon.
....
.........
https://www.zacks.com/stock/news/684919/...txt-684919